NRDL+ 2024 Annual Executive Debrief: The State of Access for Innovative Medicines in China
Back to Access360
In this inaugural annual NRDL+ debrief, we comprehensively examined pivotal developments and trends across basic medical insurance
Former CFDA Head Bi Jingquan: Challenges and Solutions in China's Innovative Medicine Market
Bi Jingquan, previously at the helm of the China Food and Drug Administration and instrumental in regulatory overhauls that transformed
Key Direction for Huiminbao Drug Formulary at China's National Two Sessions
During China's 2024 National Two Sessions in March, Wu Fan, a member of the National Committee of the
Pudong Drug Pricing Pilot
#1 Pudong reform pilot permits new drug launch pricing comparable to international markets.
On January 22nd, a joint announcement was
China's Basic Medical Insurance Data: Three Key Trends and Ecosystem Implications
The 2022 National Medical Security Industry Development Statistical Bulletin, along with the Basic Medical Insurance operation data for Q1 to
Policy Push for Long-Term Huiminbao: The Impact on Innovative Medicine
In early January, the National Administration of Financial Regulation (NAFR) issued a draft titled "Notice on Promoting the Smooth
Closing the Affordability Gap: Can China’s Commercial Health Insurance Deliver?
At the end of 2021, individual out-of-pocket (OOP) spending in China constituted 27.7% of total healthcare expenditure (THE), soaring
Fair Pricing of Pharmaceuticals: Insights into China's NRDL Negotiation
Although NRDL negotiation involves multiple aspects, at its core, the most fundamental issue is the fair pricing of innovative pharmaceuticals.
China Market Access Pathways for Innovative Medicines Infographic
Breaking from my usual bi-weekly newsletters, I have a valuable resource for you: an infographic detailing China Market Access Pathways
